Company: MIRM
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001759425-25-000014
Chunk: 161

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 161
---
 cash provided by (used in) operating activities:Stock-based compensation48,444 35,023 27,007 Depreciation and amortization23,629 10,829 3,238 Inventory reserves and firm commitment losses2,614 9,257 — Amortization of debt discount and offering costs1,661 1,117 — Loss from termination of revenue interest purchase agreement— 49,076 — Non-cash interest expense related to the revenue interest liability— 5,060 15,979 Deferred income taxes associated with an acquisition— — (6,580)Unrealized foreign exchange (gain) loss(1,231)1,764 — Non-cash lease expense1,354 620 443 Other(795)(1,054)(3,508)Change in operating assets and liabilities:Accounts receivable(11,426)(43,974)(20,727)Prepaid and other current assets(849)(3,600)(3,676)Inventory(3,166)(974)(3,448)Other assets(1,498)(511)(127)Accounts payable, accrued expenses and other liabilities40,312 30,778 7,639 Operating lease liabilities(782)(940)(711)Net cash provided by (used in) operating activities10,325 (70,944)(120,136)Investing activitiesPurchase of investments(89,026)(27,329)(132,322)Proceeds from maturities of investments19,894 153,000 140,300 Purchase of property and equipment(993)(109)(278)Cash paid for acquisition— (212,762)— Payments made for additions to intangible assets(20,000)(20,000)— Net cash (used in) provided by investing activities(90,125)(107,200)7,700 Financing activitiesProceeds from issuance of common stock in private placement, net of issuance costs— 202,204 — Proceeds from issuance of common stock in at-the-market offerings, net of issuance costs— 14,480 21,289 Proceeds from issuance of common stock in public offerings, net of issuance costs— — 86,078 Proceeds from issuance of convertible notes, net— 305,304 — Proceeds from issuance of common stock pursuant to equity plans17,699 10,470 7,272